Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers.
The eighth volume of the book features reviews on these topics:
- Key data management elements in clinical trials for oncological therapeutics
- Prospects for therapeutic targeting of microRNAs in brain tumors
- Breast cancer vaccines: current status and future approach
- Desmocollin-3 and cancer
- MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53
- Towards targeted therapy: anticancer agents targeting cell organelle mitochondria
- Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults
Audience: Pharmaceutical Scientists, Medicinal Chemists, Clinical Oncologists, Researchers in Pre-clinical studies and clinical trials
Table of Contents
Chapter 1 Key Data Management Elements In Clinical Trials For Oncological Therapeutics1. Introduction
2. Cdisc Standards Applications To Oncology Clinical Trials
2.1. Data Collection Based On Cdash Standards In Oncology Studies
2.2. The Sdtm Data Mapping Process Of Oncology Clinical Trials
2.3. The Data Analysis Of Oncology Clinical Trials By Implementing Adam Datasets
2.4. The Developing Status Of Therapeutic Area Data Standards User Guide
3. Key Perspectives Of Clinical Data In Clinical Trial Development Of Cancer Drugs
4. Key Considerations Of Crf Designs In Cancer Trials
4.1. History Of Tumor Therapy/Prior Treatment
4.2. Tumor Diagnosis
4.3. Status Rating Of Physical Performances
4.4. Questionnaire Of Quality Of Life
4.5. Body Weight
4.6. Medical Diagnosis With Molecular Biology Techniques
4.7. Biomarkers Measures
4.8. Imaging Evaluations And Tumor Lesion Measurements
4.9. Dose Given/Administration And Dose Adjustments
4.10. Adverse Reactions
4.11. Therapeutic Completion And Trial Summary
5. Risk-Based Data Management
6. Data Validation And Management In Oncology Studies
6.1. Data Management Of Subjects' Eligibility With Tumor Staging Status
6.2. Data Management On Historical Anti-Tumor Treatment
6.3. Data Management On Dose Administration
6.4. Data Management On Terminated Criteria
6.5. Data Management On Efficacy Assessment
6.6. Data Management On Safety Assessment
6.7. Data Management On External Data
7. Management Of Independent Data Monitoring Committees In Oncology Studies
7.1. Roles Of Dmc In Interim Analysis Of Oncology Studies
7.2. Management Of Statistical Processes By Dmc In Oncology Studies
7.3. Dmc Interaction With Sponsors
7.4. Dmc Interaction With Regulatory Authorities
- Concluding Remarks
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 2 Prospects For Therapeutic Targeting Of Micrornas In Brain Tumors
- Ilgiz Gareev And Ozal Beylerli
1. Introduction
2. Biogenesis And Function Of Mirna
3. Mirna-Based Therapeutic Strategies
4. Mirnas And Brain Tumors
4.1. Role Of Mirnas Dysregulation In Glioma
4.2. Role Of Mirnas Dysregulation In Meningioma
4.3. Role Of Mirnas Dysregulation In Pa
4.4. Role Of Mirnas Dysregulation In Medulloblastoma
4.5. Metastasis-Associated Mirna
5. Development And Therapeutics Of Mirna-Based Drugs For Brain Tumors
5.1. Strategies For Mirna-Based Drugs Administration To Brain Tumors
5.1.1. Intracerebroventricular And Intrathecal Administration
5.1.2. Transnasal Administration
5.2. Delivery Methods Of Mirna-Based Drugs To The Brain Tumors
5.2.1. Mirna Delivery Via Exosomes
5.2.2. Mirnas Delivery Through Nanoparticles
5.2.3. Mirna Delivery Through Viral Vectors
6. Conclusions And Future Perspectives
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 3 Breast Cancer Vaccines: Current Status And Future Approach
- Aytül Gül, Sedef Erkunt Alak, Ceren Gül, Tuğba Karakavuk, Hüseyin Can, Muhammet Karakavuk, Ahmet Efe Köseoğlu, Mert Döşkaya, Aysu Değirmenci Döşkaya, Elif Esin Hameş Tuna, Cemal Ün, Adnan Yüksel Gürüz And Levent Yeniay
- Introduction
- Probable Vaccine Antigens
- Tumor Association Antigens
- Breast Cancer Stem Cell Oncoantigens
- Neoantigens
- Vaccine Platform Technologies For Breast Cancer
- Peptide Vaccines
- Cell Based Vaccines
- Whole Tumor Cell Vaccines
- Dendritic Cell Based Vaccines
- Nucleic Acid Vaccines
- Dna Vaccines
- Rna Vaccines
- Viral Vector-Based Vaccines
- Future Perspective
- Conclusion
- List Of Abbreviations
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 4 Desmocollin-3 And Cancer
- Chandreshwar Shukla, Nayan K Jain And Bakulesh Khamar
- Introduction
- Desmocollin-3
- Dsc3 Gene And Its Expression In Cancer
- Mutations Of Dsc3 In Cancer
- Dsc3 Protein Expression
- Dsc3 Expression In Cancer
- Dsc3 Positive Cancer
- Dsc3 Negative Cancer
- Correlation Of Dsc3 In Cancer
- Correlation With Tp53 Family
- Correlation With Other Desmosomal Components
- Correlation With Hallmarks Of Cancer
- Significance Of Dsc3 As A Biomarker
- Dsc3 As A Diagnostic Biomarker
- Dsc3 As A Prognostic Marker
- Dsc3 Expression And The Effect Of Therapeutic Agents
- Chemotherapeutic Agents
- Tyrosine Kinase Inhibitors
- Hypomethylating/Demethylating Agents
- Dsc3 And Signaling Pathways
- Dsc3 And Tumor-Infiltrating Immune Cells
- Dsc3 And Immunotherapy
- Active Immunotherapy
- Conclusion
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 5 Mdm2-P53 Antagonists Under Clinical Evaluation: A Promising Cancer Targeted Therapy For Cancer Patients Harbouring Wild-Type Tp53
- Maryam Zanjirband
- Introduction
- The Tp53 Acts As A Tumour Suppressor Gene Through Inducing Cell Cycle Arrest And Apoptosis
- Use Of Mdm2-P53 Antagonists To Target P53-Mdm2 Interaction For Cancer Therapy
- Concluding Remarks
- Notes
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 6 Towards Targeted Therapy: Anticancer Agents Targeting Cell Organelle Mitochondria
- Meghana Manjunath And Bibha Choudhary
- Introduction
- Understanding The Mitochondrial Physiology
- Bioenergetics Of Mitochondria
- Calcium Signalling In Mitochondria
- Mitochondrial Fission And Fusion
- Reactive Oxygen Species (Ros) Production In Mitochondria
- Mitochondria And Cell Death
- Role Of The Mitochondria In Biosynthetic Pathways
- Oncogenic And Tumour-Suppressive Pathways Regulating Mitochondrial Metabolism And Biogenesis
- Mitochondrial Metabolism And The Immune System
- Mitochondrial Genome
- Mitochondrial Mutations In Cancer
- Transcriptomic Studies For Understanding Mitochondria
- Cancer Stem Cells And Mitochondria
- Targeting Mitochondria In Cancer Therapy
- Targeting Apoptosis
- Bcl2 Family Inhibitors
- Targeting Mitochondrial Metabolism
- Anaplerosis As A Target
- Targeting The Tca Cycle
- Targeting The Etc
- Targeting Mitochondrial Fission And Fusion
- Targeting Ros
- Targeting Cancer Stem Cells(Cscs) Using Antibiotics
- Targeting Mitochondrial Mutations Via Immune Therapy
- Online Resource Toolkit Available To Understand Mitochondrial Genomics
- Concluding Remarks
- Future Perspectives
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
Chapter 7 Anticancer Therapeutic Strategies In Gliomas: Chemotherapy, Immunotherapy, And Molecularly Targeted Therapy In Adults
- Xiaoyan Hu, Kexun Lian, Mengmeng Wang And Xun Zhang
- Introduction
- Chemotherapy
- Molecularly Targeted Therapy
- Mgmt Methylation
- Idh Mutations
- Tp53 Mutations
- Atrx Mutations
- Tert Mutations
- Chromosomal Deletions
- Immunotherapy
- Personalised Peptide Vaccines
- Dendritic Cell (Dc) Vaccine Therapy
- Car-T Cell Therapy
- Checkpoint Blockade Therapy
- Oncolytic Virus Therapy
- Conclusion
- Future Directions
- Consent For Publication
- Conflict Of Interest
- Acknowledgements
- References
- Subject Index
Author
- Atta-ur-Rahman
